Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1466 (24 June), doi:10.1136/bmj.332.7556.1466
Clinicians shouldn't be put off by its reputation as an anaesthetic and drug of abuse
| The first 150 words of the full text of this article appear below. |
Ketamine is well known as an intravenous anaesthetic agent with analgesic properties. It is also becoming well known as a drug of abuse. Less well known, however, is the fact that oral ketamine is a useful analgesic agent in cancer and chronic non-malignant pain. Indeed, its reputation as a drug of abuse may be making clinicians overcautious about its use for pain relief.
In anaesthetic practice high plasma and brain concentrations of ketamine result in dissociative anaesthesia, amnesia, a rise in arterial pressure, increased heart rate and cardiac output, and raised intracranial pressure with relative preservation of airway reflexes and respiration. Ketamine became established for use in hypovolaemic patients and in difficult locations such as battlefields because of its safety. Reports have also suggested relatively few serious adverse effects using the oral route or at subanaesthetic doses,1 2 which is also in keeping with our clinical experience. One of the
Nosa A Akporehwe, senior specialist registrar in neurological rehabilitation
Hunters Moor Regional Neurological Rehabilitation Centre, Newcastle upon Tyne NE 2 4NR
(nosa.akporehwe@nap.nhs.uk)
Paul R Wilkinson, consultant in anaesthesia and pain management
Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP
Rachel Quibell, specialist registrar in palliative care
Marie Curie Hospice, Newcastle upon Tyne NE4 6SS
Kerstin A Akporehwe, general practitioner
Mountbatten Medical Centre, Hebburn NE31 1LD
Read all Rapid Responses